April 28, local time, the governor of the Brazilian state of Sao Paulo, Doria, announced that the Butantan Institute, the country’s leading medical research institution, began producing the first batch of the country’s own research and development of Coronavirus vaccine “Butantan vaccine.”
Mr Doria said the first batch of “butantan vaccines” was produced in 1m doses. Production of the vaccine is expected to reach 18 million doses by June 15 this year.
At present, the Butantan Institute is applying to the Brazilian Health Supervision Agency for a license for the use of vaccines in human clinical trials, and once approved, the vaccines produced will be immediately used in previously planned Phase III and Phase II human clinical trial studies.
On 27 April, the Brazilian Health Supervision Authority requested the Butantan Institute to submit additional materials for vaccine approval, which it said would maintain communication with the health sector in order to provide the necessary data and instructions to facilitate the vaccine approval process, but hoped that the Health Inspectorate would expedite the approval of relevant applications.
On 26 March, the Governor of S?o Paulo, Doria, announced that the Butantan Institute was in the process of developing the country’s first vaccine, the Butantan Vaccine, and had completed pre-clinical testing.
On the same day, the Institute submitted preliminary experimental data to the Brazilian Health Supervision Authority.
It is reported that the Butantan Institute began the development of this vaccine at the end of March last year, its production is based on the virus chicken embryo culture technology.
